Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Introduction of GLP-1s

Page View:

GLP-1 New Drug R&D Service: Introduction of GLP-1s

Glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino-acid-long peptide hormone. GLP-1 exists in two equally bioactive forms, GLP-1 (7-37) amide and GLP-1 (7-36) amide. GLP-1 is a biological product derived from the post-translational processing of proglucagon. GLP-1 is secreted by the enteroendocrine L cells, but also by some neuronal populations in the hindbrain. GLP-1 potentiates insulin release and reduces glucagon’s concentration in physiological conditions.

  • GLP-1 New Drug R&D Service

    Medicilon provides GLP-1 drug discovery, CMC research (API + formulation), pharmacodynamics research, PK study, GLP-1 safety evaluation and other services. As of the end of May 2023, Medicilon has successfully assisted in the clinical approval of 7 GLP-1 drugs (3 approved by FDA and NMPA,1 approved by FDA, NMPA, and TGA) and has multiple GLP-1 projects under development.

Relevant newsRelevant news